Arbutus Biopharma
ABUS
ABUS
50 hedge funds and large institutions have $91.9M invested in Arbutus Biopharma in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 21 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
50
Holders Change
-1
Holders Change %
-1.96%
% of All Funds
1.15%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
12
Reduced
21
Closed
7
Calls
$1.05M
Puts
$683K
Net Calls
+$368K
Net Calls Change
+$224K
Top Buyers
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$6.67M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$1.45M |
| 3 |
Goldman Sachs
New York
|
+$261K |
| 4 |
JPMorgan Chase & Co
New York
|
+$223K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$180K |
Top Sellers
| 1 |
QF
QVT Financial
New York
|
-$80.9M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.48M |
| 3 |
Renaissance Technologies
New York
|
-$796K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$592K |
| 5 |
Morgan Stanley
New York
|
-$573K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$96K | -19,099 | Closed |
|
|
TSS
52
Two Sigma Securities
New York
| – | -$57K | -11,294 | Closed |
|
|
VF
53
Virtu Financial
New York
| – | -$57K | -11,287 | Closed |
|
54
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$9K | -1,792 | Closed |
|